Advanced Biomedical Technologies, Inc.
ABMT · OTC
10/31/2022 | 10/31/2021 | 10/31/2020 | 10/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.23 | -0.81 | 3.90 | 0.16 |
| FCF Yield | -20.81% | -18.25% | 5.87% | -18.22% |
| EV / EBITDA | -62.27 | -32.03 | -53.17 | -15.12 |
| Quality | ||||
| ROIC | 15.99% | 26.41% | 16.78% | 38.73% |
| Gross Margin | 81.88% | 54.50% | 58.07% | 34.84% |
| Cash Conversion Ratio | 1.42 | 1.16 | -0.96 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | 29.92% | 144.89% | – | – |
| Free Cash Flow Growth | 18.13% | -245.65% | 180.93% | 15.13% |
| Safety | ||||
| Net Debt / EBITDA | -41.00 | -18.65 | -16.06 | -8.17 |
| Interest Coverage | -0.54 | -1.23 | -1.36 | -1.85 |
| Efficiency | ||||
| Inventory Turnover | 0.20 | 0.41 | 0.52 | 0.12 |
| Cash Conversion Cycle | 1,841.01 | 873.27 | 789.35 | 4,518.94 |